Physician profile
Michael Jones
NPI 1972523991
$1,782.03
in general payments reported to CMS, 2019-2025
25 companies · $553 in 2025
The $553 reported for 2025 was more than what 82% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $93.77 · 2023: $659 · 2024: $477 · 2025: $553.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,688.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,688.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $496.97 | 2022-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $373.77 | 2022-2025 | Ingrezza |
| Corium, LLC | $120.07 | 2022-2023 | Azstarys |
| Abbvie INC. | $98.30 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $98.17 | 2024-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Axsome Therapeutics, INC. | $64.52 | 2023-2025 | Auvelity |
| Exact Sciences Corporation | $62.69 | 2023-2024 | Cologuard Collection Kit |
| Alkermes, INC. | $57.99 | 2023-2024 | Aristada, Lybalvi, Vivitrol |
| Vanda Pharmaceuticals INC. | $49.46 | 2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $44.99 | 2024-2025 | Rexulti |
| Mylan Specialty L.P. | $37.66 | 2022-2023 | Yupelri |
| Hologic Sales and Service, LLC | $35.81 | 2023 | Thinprep 2000 Processor, Aptima, Third Wave |
| Corcept Therapeutics | $31.92 | 2025 | Korlym |
| Noven Therapeutics, LLC | $27.97 | 2024 | Xelstrym, Secuado |
| Ironshore Pharmaceuticals INC. | $20.13 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $19.17 | 2023 | Perseris |
| Astellas Pharma US INC | $18.27 | 2024 | Veozah |
| Boston Scientific Corporation | $17.97 | 2024 | Wavewriter Alpha Prime 16 |
| Lundbeck LLC | $16.73 | 2023 | Rexulti |
| Novo Nordisk INC | $16.11 | 2023 | Wegovy |
| Supernus Pharmaceuticals, INC. | $15.72 | 2023 | Qelbree |
| Sunovion Pharmaceuticals INC. | $15.53 | 2022 | |
| Genzyme Corporation | $15.29 | 2023 | |
| Sanofi Pasteur INC. | $13.56 | 2023 | |
| Amgen INC. | $13.26 | 2023 | Prolia, Evenity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.